Authenticx and The FDA

Authenticx and The FDA

Exhibitor Case Studies

Information

In a focused 90-minute technical session, FDA experts reviewed our models, validation strategy, and risk-mitigation design. Their engagement and feedback emphasized the scientific rigor and responsible approach behind Authenticx technology. For customers, this reinforces confidence that Authenticx is shaping the future of post-marketing safety monitoring and enabling more consistent, accurate detection of potential safety events.
Authenticx202"STOP BY" LIVE EXHIBITOR MEETING ROOMS - JOIN HERE In 2025, Authenticx was chosen from hundreds of applicants as one of 16 organizations to present an AI-powered approach to post-marketing safety surveillance to a multidisciplinary audience of scientific and regulatory experts. The presentation showcased the use of proprietary AI models to analyze large volumes of recorded patient and healthcare professional conversations to identify and prioritize potential adverse events, product quality complaints, and special situations (or "safety events"). Emphasis was placed on model performance, risk mitigation, and workflow integration to support pharmacovigilance review and reporting. The session highlighted the potential for validated conversational AI to enhance signal detection, reduce manual review workload, and improve the timeliness and consistency of post-marketing safety activities. Authenticx sets a new standard for listening at scale with artificial intelligence. If you're interested in learning more about how our AI models help clients accurately detect safety events, we'd love to show you how!